Skip to Content

Revlimid (lenalidomide) Disease Interactions

There are 3 disease interactions with Revlimid (lenalidomide):


Lenalidomide (Includes Revlimid) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Lenalidomide is primarily excreted unchanged by the kidney. Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.


Lenalidomide (Includes Revlimid) ↔ thromboembolic events

Moderate Potential Hazard, Moderate plausibility. Applies to: History - Thrombotic/Thromboembolic Disorder, Pulmonary Embolism

Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide. Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).


Miscellaneous antineoplastics (Includes Revlimid) ↔ anemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Anemia, Neutropenia, Thrombocytopenia

Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.

Revlimid (lenalidomide) drug interactions

There are 225 drug interactions with Revlimid (lenalidomide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.